Share this article:
New Groundbreaking Research for Alzheimer’s Awareness Month
June in Alzheimer’s Awareness Month and The Alzheimer’s Association has marked June 21, the summer solstice, as the day to create a global observance and shed light on Alzheimer’s disease. “The Longest Day” initiative unites teams around the world to raise awareness, and honor the strength, passion and endurance of those facing Alzheimer’s disease.
Elsevier is pleased to announce several new titles in its neuroscience collection that focus on Alzheimer’s and neurodegenerative disease research and management. All books are available online via ScienceDirect as well as in print or e-book. Click on the links below to read a complimentary chapter from some of these ground-breaking books.
A Roadmap for Curing Cancer, Alzheimer’s, and Cardiovascular Disease, by Paul J. Marangos, defines deficiencies in academic life science research, including conflicting incentives and QA/QC issues, and offers recommendations on how to eliminate them. It provides a rationale for FDA reform, and details how a reformed NIH can partner with regulators and industry to create a NASA-type effort to speed cures of terminal diseases. Read the chapter “The Public Will Make it Happen.”
The End of Alzheimer’s: The Brain and Beyond, Second Edition, by Thomas Lewis and Clement Trempe, is the first comprehensive overview on the molecular basis of Alzheimer’s outside of the brain, merging the most recent findings within the field into a single book. It aims to educate the reader on the many overlooked aspects of Alzheimer’s disease that occur outside the brain.
Neurochemical Aspects of Alzheimer’s Disease: Risk Factors, Pathogenesis, Biomarkers, and Potential Treatment Strategies, by Akhlaq Farooqui, provides a comprehensive overview of molecular aspects of risk factors, pathogenesis, biomarkers, and therapeutic strategies.
Neuroprotection in Alzheimer’s Disease, by Illana Gozes, offers a translational point-of-view from both basic and clinical standpoints, putting it on the cusp for further clinical development with its emphasis on nerve cell protection, including the accumulation of knowledge from failed clinical trials and new advances in disease management. Read the chapter “Animal Models of Alzheimer’s Disease.”
Environmental Causes and Prevention Measures for Alzheimer’s Disease, by George Brewer, examines the increased incidence of the disease in developed countries and aims to educate neuroscientists, medical practitioners and other educated individuals on new insights into environmental causation, primarily metals.
Genes, Environment and Alzheimer’s Disease, by Orly Lazarov and Giuseppina Tesco, discusses the role that activities such as exercise can play in cardiovascular health, while also highlighting the fact that the last 10 years have brought great discoveries in the strong environmental component of brain disorders, neurodegeneration, and cognitive decline.
Intracellular Consequences of Amyloid in Alzheimer’s Disease, by Michael D’Andrea, addresses one of the more currently unresolved aspects confounding Alzheimer’s research, the significance of intraneuronal amyloid. It seeks to explain some of the unresolved questions concerning intracellular amyloid and its origin, entry, and toxicity. Read the chapter “Amyloid Basis of Alzheimer’s Disease.”
Biomarkers in Alzheimer’s Disease, by Tapan Khanrovides a comprehensive overview of all modalities of Alzheimer’s disease biomarkers, including neuroimaging, cerebrospinal fluid, genomic, and peripheral systems. Each chapter integrates molecular/cellular abnormality due to Alzheimer’s disease and technological advancement of biomarkers techniques.
Alzheimer’s Disease: Life Course Perspectives on Risk Reduction, by Amy Borenstein James Mortimer, summarizes the growing body of knowledge on the distribution and causes of Alzheimer’s disease (AD) in human populations, providing the reader with knowledge on how we define the disease and what its risk and protective factors are in the context of a life-course approach. Read the chapter “The First Case.”
Adenosine Receptors in Neurodegenerative Diseases, edited by David Blum and Luisa Lopes, covers the role of adenosine receptors in brain function, also focusing on related methodologies and perspectives in therapeutics.
Disease-Modifying Targets in Neurodegenerative Disorders: Paving the Way for Disease-Modifying Therapies, edited by Veerle Baekelandt and Evy Lobbestael, examines specific neurodegenerative disorders in comprehensive chapters written by experts in the respective fields.
Biometals in Neurodegenerative Diseases: Mechanisms and Therapeutics, edited by Anthony White, Michael Aschner, Lucio Costa and Ashley Bush, brings together major findings for ease of access to those working in the field or with an interest in biometals.
The scientific study of the nervous system is entering a new golden age. Researchers and clinicians continue to advance the treatment of conditions such as Alzheimer’s syndrome, Parkinson’s disease, epilepsy, and traumatic brain injury. Public initiatives like the federal Brain Research Through Advancing Innovative Neurotechnologies (BRAIN) program in the United States, announced in April 2013, ensure that funding and resources will continue to be applied to this rapidly growing field. Elsevier’s journals, books, eBooks, online references, and tools are respected around the world for everything from physiology and pathology to behavioral genetics and nerve repair. Our publications are a gateway to the latest advancements in neuroscience research and leading-edge data for professionals, students, and academics alike.